SCHEMBL11960332

SCHEMBL11960332

CC(C)c1cc(N2CCS(=O)(=O)CC2)ncn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 4/20 0.43
▸ HRH4 Q9H3N8 4/20 0.36
▸ CYP1A2 P05177 5/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ ALOX15 P16050 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ SOS1 Q07889 2/20 0.35
▸ KRAS P01116 1/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ HRH3 Q9Y5N1 2/20 0.34
▸ KMO O15229 1/20 0.34
▸ KDM5B Q9UGL1 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HRH2 P25021 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11960308 0.82 HRH4 (0.53) HRH4CYP1A2ALDH1A1ALOX15HSD17B10
SCHEMBL11960323 0.82 SMN1; SMN2 (0.46) LRRK2HRH4ALDH1A1CYP2C19HRH3
SCHEMBL13034784 0.80 SMN1; SMN2 (0.49) LRRK2HRH4ALDH1A1CYP2C19HRH3
SCHEMBL14872341 0.79 LRRK2 (0.41) LRRK2HRH4CYP1A2ALDH1A1ALOX15
SCHEMBL10223327 0.78 CYP2C19 (0.58) LRRK2CYP1A2ALDH1A1CYP2C19KMO
SCHEMBL16903679 0.76 LRRK2 (0.44) LRRK2CYP2C19
SCHEMBL19117543 0.76 SOS1 (0.40) LRRK2ALDH1A1SOS1KRASKDM5B
SCHEMBL6797898 0.76 AKT1 (0.42) LRRK2HRH4CYP1A2ALDH1A1ALOX15
SCHEMBL11960320 0.75 LRRK2 (0.45) LRRK2HRH4SOS1KRASCYP2C19
SCHEMBL19120153 0.74 PANK3 (0.42) LRRK2HRH4CYP1A2SOS1KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9309240-B2 Pyrazolopyridine compounds, compositions and methods of use GENENTECH, INC. (US) 2016-04-12 — — US disclosed
US-20140171408-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2014-06-19 — — US disclosed
US-20130252941-A1 PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2013-09-26 — — US disclosed
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2013-04-18 — — US disclosed
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 — — US disclosed
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE TYK2, IRAK1, IRAK4 LRRK2 1710/4885HRH4 123/4885CYP1A2 831/4885
US-20130252941-A1 PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE P2RX5, P2RX4, P2RY1 LRRK2 3622/4885HRH4 82/4885CYP1A2 75/4885
US-20140171408-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F12, CHRM1, NPY1R LRRK2 4285/4885HRH4 223/4885CYP1A2 22/4885
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F12, CHRM1, NPY1R LRRK2 4285/4885HRH4 223/4885CYP1A2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback